Hyperhidrosis in association with efavirenz

AIDS Patient Care and STDs

Volumn 23, Issue 3, 2009, Pages 143-145

  Martín, Aurelio Fuertes ^a   Cabrera Figueroa, Salvador ^a,b   De La Paz Valverde Merino, María ^a   Domínguez Gil Hurlé, Alfonso ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; CYTOCHROME P450 2D6; EFAVIRENZ; INDINAVIR; LAMIVUDINE; STAVUDINE; ZIDOVUDINE;

ADULT; ALLELE; ANAMNESIS; ARTICLE; BLOOD BRAIN BARRIER; CASE REPORT; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVENING DOSAGE; GENE DELETION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERHIDROSIS; LIPODYSTROPHY; MALE; NIGHT SWEAT; PATIENT COMPLIANCE; THERMOREGULATION;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HIV-1; HUMANS; HYPERHIDROSIS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 62949172241     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2008.0176     Document Type: Article

References (14)

1. Cheshire WP, Fealey RD. Drug-induced hyperhidrosis and hypohidrosis: Incidence, prevention and management. Drug Saf 2008;31:109-126.
2. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71-75.
3. Kappelhoff BS, van Leth F, MacGregor TR, et al. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005;10:145-155.
4. Haas DW. Will pharmacogenomic discoveries improve HIV therapeutics? Top HIV Med 2005;13:90-95.
5. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 2002;359:30-36.
6. Núñez M, González de Requena D, Gallego L, Jiménez-Nácher I, González-Lahoz J, Soriano V. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 2001;28:399-400.
7. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003;73:20-30.
8. Dahri K, Ensom MH. Efavirenz and nevirapine in HIV-1 infection: Is there a role for clinical pharmacokinetic monitoring?. Clin Pharmacokinet 2007;46:109-132.
9. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 2004;18:2391-2400.
10. Rodriguez-Novoa S, Barreiro P, Rendón A, Jiménez-Nacher I, González-Lahoz J, Soriano V. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005;40:1358-1361.
11. Crixivan® [product label]. Hertfordshire, UK: Merck Sharp & Dohme Ltd., October 2006.
12. Sustiva® [product label]. Princeton, NJ: Bristol-Myers Squibb Company, January 2007.
13. Marcy TR, Britton ML. Antidepressant-induced sweating. Ann Pharmacother 2005;39:748-752.
14. Adkins JC, Noble S. Efavirenz. Drugs 1998;56:1055-1064.